

VERNEREY Déwi  
3 le coteau  
25115 POUILLEY-LES-VIGNES  
dvernerey@chu-besancon.fr  
French citizenship  
Driving license



## Research Engineer in Epidemiology & Biostatistics (Ph.D. / + 20 years' experience)

### ➤ WORK EXPERIENCE

- Since 2013 **Research Engineer in Epidemiology & Biostatistics (permanent contract CHRU: "Ingenieur Principal")** in the Methodology and quality of life in Oncology Unit (UMQVC) at the **University hospital of Besancon**.  
Since 2021 Head office of the UMQVC  
**Teacher (vacation university)**. in statistics, data analysis and methodology in master's degree and in medical school.  
**Expert / consultancy in Methodology, Epidemiology and Biostatistic**
- 2010 – 2013 **Research Engineer in Epidemiology & Biostatistics (permanent contract INSERM)** at PARCC (Paris Cardiovascular Research Center) located in Georges Pompidou European hospital.
- 2008 – 2010 **Biostatistician (permanent contract)** at «*Genetic diseases Institute*» in Necker Hospital.
- 2006 – 2008 **Research Engineer in Statistics (fixed-term contract)** at **INSERM U535 Unit** (Epidemiologic Genetics and Human Populations Structure - Paul Brousse Hospital - Villejuif).
- 2005 **Biostatistician (fixed-term contract)** at **Sanofi Aventis R&D Center** (Chilly Mazarin)
- 2005 **Teacher at Public Health and Epidemiology Summer School** « *Ecole d'été de santé publique et d'épidémiologie* » at Paris XI University (Kremlin Bicêtre Hospital)
- 2004 – 2005 **Biostatistician (fixed-term contract)** in « **Institut Gustave Roussy** » (IGR-Villejuif) Biostatistics and Epidemiology department.

### ➤ EDUCATION

- 2013 – 2016 **PhD in epidemiology and statistics**  
Burgundy and Franche-Comté University.
- 2002 – 2003 **Master's degree in Mathematical Engineering** - major: Engineering Statistics – graduated cum laude  
Joseph Fourier University, Grenoble 38.
- 1999 – 2002 **Bachelor and Master's degree in Mathematics** - graduated cum laude  
**Two-Year University degree in Mathematics and Informatics Applied to Science**-graduated cum laude  
« UFR Sciences et Techniques » of Franche-Comté, Besançon, 25.
- 1999 **BACCALAUREAT in Science (major mathematic)** followed by a one-year preparatory classes for entrance to "Grandes Ecoles" in the field of science  
Victor Hugo High School, Besançon 25.

## ➤ ADVISORY BOARD

- Since 2017 Member of the HaliodDx's Digestive Scientific Advisory Board (2017-2019)
- Since 2017 Member of the ARCAD Foundation's Scientific Advisory Board (2017-XXXX)
- Since 2018 Member of the Canceropôle Grand Est Scientific Advisory Board (2018-XXXX)
- Since 2023 Member of the GERCOR Scientific Advisory Board (2023-XXXX)

## ➤ INTERNATIONAL AND NATIONAL RESPONSABILITIES

- Since 2017 Member of the ARCAD group
- Since 2017 Head of GERCOR statistical team (INCA's labeled data center)

## ➤ SUPERVISING

- 2016 Supervision of 3 students in Master degree in statistics (Marie Justine Paillard, Angelique Vienot and Edouard Auclin)
- Since 2017 Supervision of 2 PhD students in statistics (Angelique Vienot and Edouard Auclin)

## ➤ FIELD OF EXPERTISE

Epidemiology, Biostatistics, Clinical trials design and Analysis

Clinical Research

Oncology, Kidney and Heart Transplantation, Cardiovascular diseases, Monogenic genetic diseases (rare) & multifactorial (frequent), Pathology, Immunology, transfusion

## ➤ PUBLICATION PRODUCTION INDICATORS

Since 2005: **141** publications indexed in Pubmed

h-index (excluding self citations): **41**

## ➤ MAJOR 25 PUBLICATIONS

1. Kim S, Ghiringhelli F, de la Fouchardière C, Evesque L, Smith D, Badet N, Samalin E, Lopez-Trabada Ataz D, Parzy A, Desramé J, Baba Hamed N, Buecher B, Tougeron D, Bouché O, Dahan L, Chibaudel B, El Hajbi F, Mineur L, Dubreuil O, Ben Abdelghani M, Pecout S, Bibeau F, Herfs M, Garcia ML, Meurisse A, **Vernerey D**, Taïeb J, Borg C  
*Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.*  
**Lancet Oncology (2024)**

2. Adotevi O, **Vernerey D**, Jacoulet P, Meurisse A, Laheurte C, Almotlak H, Jacquin M, Kaulek V, Boullerot L, Malfroy M, Orillard E, Eberst G, Lagrange A, Favier L, Gainet-Brun M, Doucet L, Teixeira L, Ghrieb Z, Clairet AL, Guillaume Y, Kroemer M, Hocquet D, Moltenis M, Limat S, Quoix E, Mascaux C, Debieuvre D, Fagnoni-Legat C, Borg C, Westeel V  
*Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study.*  
**Journal of Clinical Oncology (2023)**
3. André T, Tougeron D, Piessen G, de la Fouchardière C, Louvet C, Adenis A, Jary M, Tournigand C, Aparicio T, Desrame J, Lièvre A, Garcia-Larnicol ML, Pudlarz T, Cohen R, Memmi S, **Vernerey D**, Henriques J, Lefevre JH, Svrcek M.  
*Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.*  
**Journal of Clinical Oncology (2023)**
4. Basile D, Broudin C, Emile JF, Falcoz A, Pagès F, Mineur L, Bennouna J, Louvet C, Artru P, Fratte S, Ghiringhelli F, André T, Derangère V, **Vernerey D**, Taieb J, Svrcek M; for PRODIGE investigators, GERCOR, Fédération Française de Cancerologie Digestive, and UNICANCER.  
*Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).*  
**Annals of Oncology (2023)**
5. Fontana E, Meyers J, Sobrero A, Iveson T, Shields AF, Taieb J, Yoshino T, Souglakos I, Smyth EC, Lordick F, Moehler M, Giraut A, Harkin A, Labianca R, Meyerhardt J, André T, Boukovinas I, Lonardi S, Saunders M, **Vernerey D**, Oki E, Georgoulas V, Ben-Aharon I, Shi Q  
*Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin.*  
**Journal of Clinical Oncology (2021)**
6. Taieb J, Taly V, Henriques J, Bourreau C, Mineur L, Bennouna J, Desrame J, Louvet C, Lepere C, Mabro M, Egreteau J, Bouche O, Mulot C, Hormigos K, Chaba K, Mazard T, de Gramont A, **Vernerey D**, André T, Laurent-Puig P.  
*Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial.*  
**Clinical Cancer Research (2021)**
7. André T, Meyerhardt J, Iveson T, Sobrero A, Yoshino T, Souglakos I, Grothey A, Niedzwiecki D, Saunders M, Labianca R, Yamanaka T, Boukovinas I, **Vernerey D**, Meyers J, Harkin A, Torri V, Oki E, Georgoulas V, Taieb J, Shields A, Shi Q.  
*Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.*  
**Lancet Oncology (2020)**
8. Cohen R, **Vernerey D**, Bellera C, Meurisse A, Henriques J, Paoletti X, Rousseau B, Alberts S, Aparicio T, Boukovinas I, Gill S, Goldberg RM, Grothey A, Hamaguchi T, Iveson T, Kerr R, Labianca R, Lonardi S, Meyerhardt J, Paul J, Punt CJA, Saltz L, Saunders MP, Schmoll HJ, Shah M, Sobrero A, Souglakos I, Taieb J, Takashima A, Wagner AD, Ychou M, Bonnetain F, Gourgou S, Yoshino T, Yothers G, de Gramont A, Shi Q, André T; ACCENT Group.  
*Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.*  
**European Journal of Cancer (2020)**
9. Grothey A, Sobrero A, Shields A, Yoshino T, Paul J, Taieb J, Souglakos L, Shi Q, Kerr R, Labianca R, Meyerhardt J, **Vernerey D**, Yamanaka T, Boukovinas L, Meyers J, Renfro L, Niedzwiecki D, Torri V, Sargent D, Andre T, Iveson T  
*Duration (3 versus 6 months) of adjuvant oxaliplatin and fluoropyrimidine chemotherapy for stage III colon cancer*  
**New England Journal of Medicine (2018)**
10. Auclin E, André T, Taieb J, Banzi M, Van Laethem JL, Tabernero J, Hickish T, de Gramont A, **Vernerey D**  
*Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial.*  
**British Journal of Cancer (2019)**

11. Grothey A, Sobrero A, Shields A, Yoshino T, Paul J, Taieb J, Souglakos L, Shi Q, Kerr R, Labianca R, Meyerhardt J, **Vernerey D**, Yamanaka T, Boukovinas L, Meyers J, Renfro L, Niedzwiecki D, Torri V, Sargent D, Andre T, Iveson T  
*Duration (3 versus 6 months) of adjuvant oxaliplatin and fluoropyrimidine chemotherapy for stage III colon cancer*  
**New England Journal of Medicine (2018)**
12. Thierry A, **Vernerey D**, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, Hug de Larauze M, Paget-Bailly S, Chibaudel B, Bez J, Dauba J, Louvet C, Lepere C, Dupuis O, Becouarn Y, Mabro M, Egretteau J, Bouche O, Deplanque G, Ychou M, Galais MP, Ghiringhelli F, Dourthe LM, Bachet JB, Khalil A, Bonnetain F, de Gramont A, Taieb J  
*Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label, International Duration Evaluation of Adjuvant (IDEA) France phase III trial*  
**Journal of Clinical Oncology (2018)**
13. Auclin E, Zaanani A, **Vernerey D**, Douard R, Gallois C, Laurent-Puig P, Bonnetain F, Taieb J.  
*Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy.*  
**Annals of Oncology (2017)**
14. Vienot A, Beinse G, Louvet C, de Mestier L, Meurisse A, Fein F, Heyd B, Cleau D, d' Engremont C, Dupont-Gossart A-C, Lakkis Z, Tournigand C, Bouché O, Rousseau B, Neuzillet C, Bonnetain F, Borg C, **Vernerey D**  
*Development and validation of a prognostic nomogram and score to predict overall survival and usefulness of second-line chemotherapy in advanced pancreatic adenocarcinoma*  
**Journal of the National Cancer Institute (2017)**
15. **Vernerey D**, Huguet F, Vienot A, Goldstein D, Paget-Bailly S, Van Laethem J-L, Glimelius B, Artru P, Moore MJ, André T, Mineur L, Chibaudel B, Benetkiewicz M, Louvet C, Hammel P, Bonnetain F  
*Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP).*  
**British Journal of Cancer (2016)**
16. Jary M, Lecomte T, Bouché O, Kim S, Dobi E, Queiroz L, Ghiringhelli F, Etienne H, Léger J, Godet Y, Balland J, Lakkis Z, Adotevi O, Bonnetain F, Borg C, **Vernerey D**  
*Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score.*  
**International Journal of Cancer (2016)**
17. André T, de Gramont A, **Vernerey D**, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriver A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maertense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF, de Gramont  
*Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.*  
**Journal of Clinical Oncology. (2015)**
18. Tournigand C, Chibaudel B, Samson B, Scheithauer W, **Vernerey D**, Mésange P, Lledo G, Viret F, Ramée JF, Tubiana-Mathieu N, Dauba J, Dupuis O, Rinaldi Y, Mabro M, Aucoin N, Latreille J, Bonnetain F, Louvet C, Larsen AK, André T, de Gramont A  
*Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.*  
**The Lancet Oncology. (2015)**
19. Aubert O\*, Kamar N\*, **Vernerey D\***, Viglietti D, Martinez F, Duong-Van-Huyen J-P, Eladari D, Empana J-P, Rabant M, Verine J, Rostaing L, Congy N, Guilbeau-Frugier C, Mourad G, Garrigue V, Morelon E, Giral M, Kessler M, Ladrière M, Delahousse M, Glotz D, Legendre C, Jouven X, Lefaucheur C, Loupy A  
*Long-term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study.*  
**British Medical Journal. (2015)**  
\*Co first authorship

20. Loupy A\*, **Vernerey D\***, Viglietti D\*, Aubert O, Duong Van Huyen J-P, Empana J-P, Bruneval P, Glotz D, Legendre C, Jouven X, Lefaucheur C  
*Determinants and Outcomes of Accelerated Arteriosclerosis: Major Impact of Circulating Antibodies.*  
**Circulation Research (2015)**  
\*Co first authorship
21. Loupy A\*, **Vernerey D\***, Tinel C, Aubert O, Duong van Huyen J-P, Rabant M, Verine J, Nochy D, Empana J-P, Martinez F, Glotz D, Jouven X, Legendre C, Lefaucheur C Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.  
**Journal of the American Society of Nephrology (2015)**  
\*Co first authorship
22. Jary M\*, **Vernerey D\***, Lecomte T, Dobi E, Ghiringhelli F, Monnier F, Godet Y, Kim S, Bouche O, Fratte S, Goncalves A, Leger J, Queiroz L, Adotevi O, Bonnetain F, Borg C  
*Prognostic Value of Angiopoietin-2 for death risk stratification in Patients with Metastatic Colorectal Carcinoma.*  
**Cancer Epidemiology, Biomarkers & Prevention (2015)**  
\*Co first authorship
23. Loupy A, Lefaucheur C, **Vernerey D**, Prugger C, Duong van Huyen J-P, Mooney N, Suberbielle C, Frémeaux-Bacchi V, Méjean A, Desgrandchamps F, Anglicheau D, Nochy D, Charron D, Empana J-P, Delahousse M, Legendre C, Glotz D, Hill GS, Zeevi A, Jouven X *Complement-binding anti-HLA antibodies and kidney-allograft survival.*  
**New England Journal of Medicine (2013)**
24. Lefaucheur C, Loupy A, **Vernerey D**, Duong-Van-Huyen J-P, Suberbielle C, Anglicheau D, Vérine J, Beuscart T, Nochy D, Bruneval P, Charron D, Delahousse M, Empana J-P, Hill GS, Glotz D, Legendre C, Jouven X  
*Antibody-mediated vascular rejection of kidney allografts: a population-based study.*  
**The Lancet (2013)**
25. Mustafic H, Jabre P, Caussin C, Murad MH, Escolano S, Tafflet M, Périer M-C, Marijon E, **Vernerey D**, Empana J-P, Jouven X  
*Main air pollutants and myocardial infarction: a systematic review and meta-analysis.*  
**JAMA (2012)**

## ➤ MAJOR COMMUNICATIONS

**Vernerey D**, Huguet F, Vienot A, Goldstein D, Paget-Bailly S, Van Laethem J-L, Glimelius B, Artru P, Moore MJ, André T, Mineur L, Chibaudel B, Benetkiewicz M, Louvet C, Hammel P, Bonnetain F  
*Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)*

- Oral Communication at : the Annual meeting of the French Pancreatic Club in 2014, Paris, France; the Annual meeting of the European Pancreatic Club in 2015, Toledo, Spain. the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in 2015, San Francisco, United States of America; the European Society for Medical Oncology World Congress on Gastrointestinal Cancer in 2014, Barcelona, Spain.
- Poster discussion at the American Society of Clinical Oncology Annual meeting in 2014, Chicago, United States of America.
- Selection for poster of distinction at the American Pancreatic Association in 2015, San Diego, United States of America.

E. Auclin, T. Andre, J. Taieb, M. Banzi, J.-L. van Laethem, J. Tabernero, T. Hickish, A. De Gramont, **D. Vernerey**

*Postoperative carcinoembryonic antigen (CEA) association with survival and oxaliplatin benefit in stage II colon cancer (CC): post hoc analysis of the MOSAIC trial*

- Poster discussion at the European Society for Medical Oncology Annual meeting in 2018, Munich, Germany.

## ➤ AWARDS

**Vernerey D**, Huguet F, Vienot A, Goldstein D, Paget-Bailly S, Van Laethem J-L, Glimelius B, Artru P, Moore MJ, André T, Mineur L, Chibaudel B, Benetkiewicz M, Louvet C, Hammel P, Bonnetain F  
*Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)*

- Best Abstract in Clinical Science at the Annual meeting of the French Pancreatic Club in 2014, Paris, France
- Best Abstract in Clinical Science at the Annual meeting of the European Pancreatic Club in 2015, Toledo, Spain.

Jary M, Lecomte T, Bouché O, Kim S, Dobi E, Queiroz L, Ghiringhelli F, Etienne H, Léger J, Godet Y, Balland J, Lakkis Z, Adotevi O, Bonnetain F, Borg C, **Vernerey D**  
*Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score*

- Best Abstract in Colorectal Cancer at the JFHOD annual congress in 2016, Paris, France

C. Neuzillet, A. Casadei Gardini, B. Brieu, C. Vivaldi, C. Smolenschi, G. Brandi, D. Tougeron, R. Filippi, A. Vienot, N. Silvestris, A.-L. Pointet, S. Murgioni, B. Rousseau, M. Scartozzi, L. Dahan, T. Boussaha, S. Crusz, A. Meurisse, A. Lievre, **D. Vernerey**  
*Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations*

- Best Poster at the European Society for Medical Oncology Annual meeting in 2018, Munich, Germany.

31/05/2024

